Emergent BioSolutions (NYSE:EBS) Trading Up 3.2% – What’s Next?

Emergent BioSolutions Inc. (NYSE:EBS) shares were up 3.2% during trading on Monday . The company traded as high as $9.74 and last traded at $9.65. Approximately 525,477 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 3,530,859 shares. The stock had previously closed at $9.35.

Wall Street Analyst Weigh In

EBS has been the topic of a number of research reports. Benchmark restated a “buy” rating and set a $8.00 price objective on shares of Emergent BioSolutions in a research report on Friday, August 16th. Rodman & Renshaw restated a “buy” rating and set a $16.00 price target on shares of Emergent BioSolutions in a report on Friday, September 13th.

Emergent BioSolutions Stock Up 8.9 %

The company has a market capitalization of $533.45 million, a P/E ratio of -0.90 and a beta of 1.59. The stock has a 50-day moving average price of $8.31 and a 200-day moving average price of $7.04. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.06 and a quick ratio of 0.54.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($1.35). Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. The business had revenue of $254.70 million during the quarter, compared to the consensus estimate of $199.47 million. During the same period last year, the business posted ($1.06) earnings per share. On average, research analysts predict that Emergent BioSolutions Inc. will post -1.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Emergent BioSolutions

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Susquehanna Fundamental Investments LLC bought a new position in shares of Emergent BioSolutions during the 1st quarter worth about $300,000. BNP Paribas Financial Markets grew its stake in Emergent BioSolutions by 155.3% in the first quarter. BNP Paribas Financial Markets now owns 163,589 shares of the biopharmaceutical company’s stock valued at $414,000 after acquiring an additional 99,520 shares during the period. Federated Hermes Inc. grew its stake in Emergent BioSolutions by 1,314.0% in the second quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock valued at $1,864,000 after acquiring an additional 253,960 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Emergent BioSolutions during the first quarter valued at approximately $57,000. Finally, Vanguard Group Inc. raised its position in shares of Emergent BioSolutions by 14.7% during the first quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock worth $8,631,000 after purchasing an additional 436,911 shares during the period. 78.40% of the stock is owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.